One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress.

[1]  D. Drucker,et al.  The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice , 2010, Diabetologia.

[2]  J. Holst,et al.  Improved tolerance to sequential glucose loading (Staub-Traugott effect): size and mechanisms. , 2009, American journal of physiology. Endocrinology and metabolism.

[3]  M. Taskinen,et al.  One-Year Treatment With Exenatide Improves β-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients , 2009, Diabetes Care.

[4]  K. Cianflone,et al.  Intestinally derived lipids: metabolic regulation and consequences--an overview. , 2008, Atherosclerosis. Supplements.

[5]  K. Adeli,et al.  Postprandial dyslipidemia in insulin resistance: mechanisms and role of intestinal insulin sensitivity. , 2008, Atherosclerosis. Supplements.

[6]  R. Bergman,et al.  Exenatide can reduce glucose independent of islet hormones or gastric emptying. , 2008, American journal of physiology. Endocrinology and metabolism.

[7]  Martin Adiels,et al.  Overproduction of Very Low–Density Lipoproteins Is the Hallmark of the Dyslipidemia in the Metabolic Syndrome , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[8]  Dennis D. Kim,et al.  Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study. , 2008, Clinical therapeutics.

[9]  R. DeFronzo,et al.  Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. , 2008, American journal of physiology. Endocrinology and metabolism.

[10]  P. Nilsson,et al.  Characterization of the influence of vildagliptin on model-assessed -cell function in patients with type 2 diabetes and mild hyperglycemia. , 2008, The Journal of clinical endocrinology and metabolism.

[11]  E. Ferrannini,et al.  Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions. , 2007, Diabetes care.

[12]  R. DeFronzo,et al.  Mathematical Modeling Shows Exenatide Improved β-Cell Function in Patients with Type 2 Diabetes Treated with Metformin or Metformin and a Sulfonylurea , 2006, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[13]  D. Drucker,et al.  The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes , 2006, The Lancet.

[14]  R. Heine,et al.  Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes , 2005, Annals of Internal Medicine.

[15]  P. Tso,et al.  GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats. , 2005, American journal of physiology. Gastrointestinal and liver physiology.

[16]  R. Heine,et al.  Postprandial dysmetabolism and cardiovascular disease in type 2 diabetes , 2005, Postgraduate Medical Journal.

[17]  A. Ceriello.  Postprandial hyperglycemia and diabetes complications: is it time to treat? , 2005, Diabetes.

[18]  K. Leunissen,et al.  N ϵ-(carboxymethyl)lysine, N ϵ-(carboxyethyl)lysine and vascular cell adhesion molecule-1 (VCAM-1) in relation to peritoneal glucose prescription and residual renal function; a study in peritoneal dialysis patients , 2004 .

[19]  M. Taskinen,et al.  What does postprandial hyperglycaemia mean? , 2004, Diabetic medicine : a journal of the British Diabetic Association.

[20]  M. Taskinen.  Diabetic dyslipidaemia: from basic research to clinical practice* , 2003, Diabetologia.

[21]  H. Ginsberg.  New Perspectives on Atherogenesis: Role of Abnormal Triglyceride-Rich Lipoprotein Metabolism , 2002, Circulation.

[22]  R. Heine,et al.  Measurement of low-density lipoprotein particle size by high-performance gel-filtration chromatography. , 1997, Clinical chemistry.

[23]  T. D. de Bruin,et al.  Triglyceride‐rich lipoproteins in non‐insulin‐dependent diabetes mellitus: post‐prandial metabolism and relation to premature atherosclerosis , 1996, European journal of clinical investigation.

[24]  M. Taskinen,et al.  Effect of Insulin Therapy on Metabolic Fate of Apolipoprotein B–Containing Lipoproteins in NIDDM , 1990, Diabetes.

[25]  M. Taskinen,et al.  Insulin Therapy Induces Antiatherogenic Changes of Serum Lipoproteins in Noninsulin‐Dependent Diabetes , 1988, Arteriosclerosis.

[26]  C. Agardh,et al.  Improvement of the Plasma Lipoprotein Pattern After Institution of Insulin Treatment in Diabetes Mellitus , 1982, Diabetes Care.